LB Pharmaceuticals Inc Common Stock (LBRX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $42.47 (+0.78%), Market cap $0.85B, 52-week low–high $14.61 ~ $32.88.
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Financial statements, price targets, institutional (13F) holdings and related news for LB Pharmaceuticals Inc Common Stock are updated in real time on BlackAll Trade.
LB Pharmaceuticals Inc Common Stock trades at $42.47 (+0.78%). Real-time quotes and charts are available on BlackAll Trade.
LB Pharmaceuticals Inc Common Stock has a market cap of about $0.85B.
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is